Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule.

Case Presentation A 36 year - old man with Fuchs' dystrophy underwent combined phacoemulsification and DSAEK of the right eye. Immediately postoperatively, ...

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD), setting it on course to become the first non-steroidal ...

The association of Duchenne muscular dystrophy with another central nervous system disorder, autism spectrum disorder/pervasive developmental disorder, which we describe, ...

Aim: To determine whether thermography can be used to evaluate bleb function. Methods: The surface temperatures of filtering blebs from 39 eyes of 33 post-trabeculectomy patients were measured using ...